Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease
Comparison of Effectiveness in Patients of Gastroesophageal Reflux Disease Taking Esomeprazole Versus Vonoprazan.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab Province
-
Dera Ghazi Khan, Punjab Province, Pakistan, 32200
- Allama Iqbal Teaching Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any gender
- Aged 18 to 65 years
- Presenting with GERD
Exclusion Criteria:
- Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records.
- Any previous history of malignancy accessed from medical records.
- Pregnancy and Lactation
- Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids.
- History of drug allergy to proton pump Inhibitors (PPIs).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group-A
Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.
|
Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.
|
|
Experimental: Group-B
Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.
|
Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sufficient relief
Time Frame: 4 weeks
|
The frequency of patients who achieved sufficient relief was noted.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Faraz Ahmad, Allama Iqbal teaching hospital Dera Ghazi Khan
- Study Director: Mujahid Iqbal, FCPS, Allama Iqbal teaching hospital Dera Ghazi Khan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Esophageal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Gastroesophageal Reflux
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Sulfoxides
- Sulfur Compounds
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Benzimidazoles
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Omeprazole
- Esomeprazole
- 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
Other Study ID Numbers
Other Study ID Numbers
- Dr-Faraz-DGK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.